v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Clyra Medical Technologies [Member]
Common Stock [Member]
Clyra Medical Technologies [Member]
Additional Paid-in Capital [Member]
Clyra Medical Technologies [Member]
Retained Earnings [Member]
Clyra Medical Technologies [Member]
AOCI Attributable to Parent [Member]
Clyra Medical Technologies [Member]
Noncontrolling Interest [Member]
Clyra Medical Technologies [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
Common Stock [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
Additional Paid-in Capital [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
Retained Earnings [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
AOCI Attributable to Parent [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
Noncontrolling Interest [Member]
BioLargo Energy Technologies, Inc (BETI) [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Balance (in shares) at Dec. 31, 2024                         301,274,243          
Balance at Dec. 31, 2024                         $ 202 $ 158,332 $ (149,500) $ (183) $ (2,795) $ 6,056
Sale of common stock for cash, net of offering costs of $15 (unaudited) (in shares)                         0          
Issuance of common stock for services (unaudited) (in shares)                         220,330          
Issuance of common stock for services (unaudited)                         $ 0 61 0 0 0 61
Stock option compensation expense (unaudited)                         0 409 0 0 0 409
Clyra Medical stock option compensation expense (unaudited) $ 0 $ 0 $ 0 $ 0 $ 206 $ 206                        
Clyra Medical dividend Series A Preferred stock (unaudited) 0 0 0 0 (86) (86)                        
Clyra Medical fair value warrant issued with debt (unaudited) 0 0 0 0 69 69                        
Noncontrolling interest allocation (unaudited)                         0 (522) 0 0 522 0
Net loss (unaudited)                         0 0 (1,155) 0 (766) (1,921)
Foreign currency translation (unaudited)                         $ 0 0 0 (20) 0 (20)
Balance (in shares) at Mar. 31, 2025                         301,760,373          
Balance at Mar. 31, 2025                         $ 202 158,265 (150,655) (203) (2,519) 5,090
Sale of common stock for cash, net of offering costs of $15 (unaudited)                         $ 0 (15) 0 0 0 (15)
Stock option exercise (unaudited) (in shares)                         265,800          
Stock option exercise (unaudited)                         $ 0 0 0 0 0 0
Clyra Medical stock issued for services (unaudited) 0 0 0 0 36 36                        
Clyra Medical stock unit offering (unaudited) 0 0 0 0 295 295                        
Balance (in shares) at Dec. 31, 2025                         317,377,777          
Balance at Dec. 31, 2025                         $ 213 165,316 (161,280) (207) (2,516) 1,526
Sale of common stock for cash, net of offering costs of $15 (unaudited) (in shares)                         1,539,744          
Sale of common stock for cash, net of offering costs of $15 (unaudited)                         $ 1 255 0 0 0 256
Issuance of common stock for services (unaudited) (in shares)                         282,407          
Issuance of common stock for services (unaudited)                         $ 0 46 0 0 0 46
Stock option compensation expense (unaudited)                         $ 0 286 0 0 0 286
Common stock issued as a fee (unaudited) (in shares)                         500,000          
Common stock issued as a fee (unaudited)                         $ 0 85 0 0 0 85
Clyra Medical stock option compensation expense (unaudited) 0 0 0 0 413 413                        
Clyra Medical dividend Series A Preferred stock (unaudited) 0 0 0 0 (86) (86)                        
Clyra Medical fair value warrant issued with debt (unaudited) $ 0 $ 0 $ 0 $ 0 $ 232 $ 232                        
BETI unit offering (unaudited)             $ 0 $ 0 $ 0 $ 0 $ 462 $ 462            
Noncontrolling interest allocation (unaudited)                         0 (641) 0 0 641 0
Net loss (unaudited)                         0 0 (2,286) 0 (1,119) (3,405)
Foreign currency translation (unaudited)                         $ 0 0 0 (2) 0 (2)
Balance (in shares) at Mar. 31, 2026                       9,730,691 319,699,928          
Balance at Mar. 31, 2026                         $ 214 $ 165,347 $ (163,566) $ (209) $ (1,973) $ (187)